Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2369
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review ; volume:15 ; number:1 ; day:15 ; month:1 ; year:2014 ; pages:1-17 ; date:12.2014
BMC nephrology ; 15, Heft 1 (15.1.2014), 1-17, 12.2014
- Creator
-
Huang, Yunyu
- Contributor
-
Zhou, Qiyun
Haaijer-Ruskamp, Flora M.
Postma, Maarten J.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2369-15-15
- URN
-
urn:nbn:de:1111-201608132046
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huang, Yunyu
- Zhou, Qiyun
- Haaijer-Ruskamp, Flora M.
- Postma, Maarten J.
- SpringerLink (Online service)
Other Objects (12)
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
![Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker in Cerebral Arteriogenesis
Contribution of angiotensin converting enzyme to angiotensin receptor blocker induced angio-oedema
Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers
Angiotensin-I-Converting-Enzyme [Angiotensin-Converting-Enzyme] bei Lungenerkrankungen und Sekundärerkrankungen
Veränderungen des Angiotensin-I-Converting-Enzyms [Angiotensin-Converting-Enzyms] bei Schilddrüsenfunktionsstörungen
Angiotensin-converting-enzyme-Hemmung
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?